N/A N=1,938 Proactive Outreach for Smokers in VA Mental Health
Smoking
Primary: Number of Participants With Cotinine-Validated Abstinence From Smoking — 36; 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,199 The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Primary: Placebo-Controlled Phase: Time to Confirmed Disease Progression (CDP) Confirmed After At Least 3 Months (Number of Participants With CDP After At Least 3 Months) — 73…
N/A N=383 Clinical Implementation of Carrier Status Using Next Generation Sequencing
Genetic Disorders
Primary: Number of Patients That Receive Carrier Testing and Have Results to Return — 9; 155 Participants
N/A N=503 Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s
Correction of Nasolabial Folds
Primary: Incidence of Device-related Adverse Events — 16 Participants
Phase 3 N=290 A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) — 28.3; 58.6 percentage of participants — p=0.001
Phase 3 N=109 A Study Of Galcanezumab In Participants With Episodic Cluster Headache
Episodic Cluster Headache
Primary: Overall Mean Change From Baseline in Number of Weekly Cluster Headache Attacks — -5.22; -8.69 Cluster Headache Attacks per Week — p=0.036
Phase 2 N=35 Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Esophageal Cancer · Gastroesophageal Junction Cancer
Primary: 2-month Progression-free Survival (PFS) of Sorafenib in Patients With Metastatic or Recurrent Esophageal and Gastroesophageal (GE) Junction Cancer. — 20; 14; 1…
N/A N=204 Comparison of Efficacy on Healing, and Safety of Two Dressings Urgotul and TulleGras MS on Surgical Acute Wounds.
Surgical Acute Wounds
Primary: Percentage of Patients With Complete Healing (100% of Epithelialization). — 77; 67 Participants
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
Phase 1 N=24 A Study of LY3143753 and LY3185643 in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 2 N=31 Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
Obsessive Compulsive Disorder
Primary: Yale-Brown Obsessive Compulsive Scale, Child Version (CYBOCS) — 28.20; 29.0; 26.67; 27.11 units on a scale
Phase 2 N=105 Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF
Heart Failure
Primary: Peak VO2 — 13.4; 13.8; 13.7; 13.6 ml/kg/min — p=0.2650
Phase 2 N=475 A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Migraine
Primary: Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6 — 0.06; -1.19; -2.25; -1.83 Days — p=<0.001
N/A N=112 Oxytocin in Cocaine Dependence
Cocaine Dependence
Primary: Subjective Stress Response TSST — 5.33; 5.28; 2.05; 2.13 units on a scale
N/A N=109 Tobacco Dependence Treatment for Asian Americans
Tobacco Dependence
Primary: 12-month Abstinence — 21; 6 Participants — p=<0.01